GLP-3 RT

GLP-3 RT — Triple Receptor Agonist Research Peptide
RT3 is a next-generation research peptide engineered to simultaneously engage three metabolic receptor targets: GLP-1, GIP, and glucagon receptors. This triple agonist mechanism represents a significant advancement over single- and dual-receptor compounds in preclinical metabolic research.
Mechanism Of Action
RT3 activates glucagon-like peptide-1 (GLP-1) receptors to potentiate glucose-dependent insulin secretion, glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance incretin signaling, and glucagon receptors to promote energy expenditure and lipid oxidation. The combined activation of all three pathways creates a synergistic metabolic effect studied extensively in preclinical models of obesity and insulin resistance.
Research Applications
Metabolic pathway modulation and energy homeostasis
Insulin sensitivity and glucose regulation studies
Appetite signaling and food intake research
Body composition and lipid metabolism investigations
Comparative studies with single- and dual-receptor agonists
Product Specifications
Quantity: Varied per vial
Purity: ≥99% (HPLC verified)
Form: Lyophilized powder
Storage: Refrigerate after reconstitution
Testing: USA lab tested, COA available
For research purposes only. Not for human use or consumption.